Lixte Biotechnology Holdings, Inc. announced that On November 6, 2022, the Board of Directors of the Company approved the following: Promoted Eric Forman, the Company's Chief Administrative Officer, to Vice President and Chief Operating Officer, and increased his annual salary from $175,000 to $200,000 per year. Authorized the issuance of stock options to Dr. John S. Kovach, Eric J. Forman, Dr. James S. Miser and Robert N. Weingarten to each purchase 200,000 shares of the Company's common stock, exercisable for a period of five years at $2.00 per share, vesting 25% on the issuance date and 25% on each anniversary date thereafter until fully vested, subject to continued service. The closing market price of the Company's common stock on November 4, 2022, was $0.5025 per share.